z-logo
open-access-imgOpen Access
The Leading Concerns of American Women with Nausea and Vomiting of Pregnancy Calling Motherisk NVP Helpline
Author(s) -
Svetlana Madjunkova,
Caroline Maltepe,
Gideon Koren
Publication year - 2013
Publication title -
obstetrics and gynecology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.648
H-Index - 13
eISSN - 1687-9589
pISSN - 1687-9597
DOI - 10.1155/2013/752980
Subject(s) - medicine , nausea , pregnancy , ondansetron , vomiting , hyperemesis gravidarum , breastfeeding , helpline , obstetrics , pediatrics , family medicine , gynecology , intensive care medicine , anesthesia , emergency medicine , genetics , biology
Background . Nausea and vomiting of pregnancy (NVP) is the most common medical condition of pregnancy, affecting up to 85% of expecting mothers. In the USA, there is no FDA-approved medication for the treatment of NVP. Objective . To identify the primary concerns of American women leading them to contact the Motherisk NVP Helpline and to characterize the severity of their symptoms and therapy offered in order to develop improved and customized counseling for them. Methods . We reviewed the intake forms of the American women who called the NVP Helpline from 2008 to 2012. We extracted their state of residence, demographic data, severity of NVP symptoms, and other available clinical characteristics. Results . A total of 195 forms were reviewed. Of these, 86% called for information on management of NVP with/without questions about fetal drug safety, while 14% called solely about drug safety during pregnancy/breastfeeding. The majority of women were Caucasian, in their thirties, educated, employed, married and in their second pregnancy. Of them 95% were suffering from moderate-to-severe condition with 13% having hyperemesis gravidarum. Conclusion . American women need more information on the management of NVP and on a variety of its aspects in addition to the safety and effectiveness of antiemetic medications. Their leading concern was the use of doxylamine and vitamin B6 combination for NVP treatment followed by the use of ondansetron.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom